Here are three insights:
1. The company’s shares closed at $49.23 with Zacks issuing a “buy” ranking.
2. With a market cap. of $920 million, Mazor has an anticipated long-term earnings per share growth of 7.9 percent.
3. The company is outperforming the industry, with its shares moving 121.5 percent in the past year, compared to the industry’s 6.3 percent increase.
More articles on devices:
Medtronic to study Infuse in PLF, TLIF spine surgeries in new pilot trials: 5 things to know
Medtronic, NuVasive, InVivo Therapeutics & more: 6 device company notes
Stryker completes Novadaq Technologies acquisition: 3 insights
